ClinicalTrials.gg
RecruitingNCT06434701SPICEUpdated Mar 14, 2025

Severe COVID-19 Infection in Children Presenting to EDs in Israel and England

An interventional study of Nasopharyngeal swab sampling for COVID-19 in COVID-19 and Inflammatory Response, sponsored by Hadassah Medical Organization. Recruiting at 6 sites in Israel. Open to participants aged 0 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Hadassah Medical Organization · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Not applicable
Ages
0 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 91 studies in COVID-19 with a site in Israel — 4 open to participants now, 7 under way, 3 of them phase 3. COVID-19 · Israel.

Planned enrollment
12th of 61
500 · median 56
Started
2024
with 1 other
No phase
19 of 91
2 open now
Registered
89th of 91
by date
Lead sponsor
6 of 91
Hadassah Medical Organization

Among the 91 studies in COVID-19 with a site in Israel, this one is the 12th largest by planned enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2024, is one of 19 with no phase, and was the 89th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 91 studies in COVID-19 with a site in Israel are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 0 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in COVID-19 with a site in Israel, or all of them as a file.
02

Study summary

Even though the COVID-19 pandemic is no longer at its peak, the threat still lingers. Engaging in prospective surveillance studies will enable us to monitor the disease and prepare for any potential resurgence. COVID-19 surveillance studies are essential tools for policymakers to make informed decisions, allocate resources, and develop strategies to control the spread of the virus and protect public health.

The objective of this surveillance study is to prospectively assess in-hospital severe morbidity related to COVID-19 infection in children who present to the Pediatric Emergency Department (ED).

A prospective multicenter study will be conducted across eight EDs in Israel and five EDs in the United Kingdom. The study population will include children aged 16 years or younger with a severe acute COVID-19 infection. Confirmation of acute COVID-19 infection will be based on polymerase chain reaction nasopharyngeal swab testing. The study will also include patients diagnosed with multisystem inflammatory syndrome in children (MIS-C), as defined by the CDC.

03

Conditions studied

  • COVID-19
  • Inflammatory Response

Browse trials for

04

Who can participate

Ages eligible
0 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. SACI

    Patients aged 16 years or younger with a positive COVID-19 PCR nasopharyngeal swab testing or bronchoalveolar sample who meet the definition of SACI:

    • Receive oxygen via low-flow nasal cannula or oxygen mask, high-flow nasal cannula, bilevel or continuous positive airway pressure machine, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) Or
    • Admitted to ICU
  2. MIS-C Patients aged 16 years or younger diagnosed with MIS-C
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Severe acute COVID-19 infection

    Nasopharyngeal swab sampling for COVID-19

    Diagnostic Test: Nasopharyngeal swab sampling for COVID-19

Interventions

  • Diagnostic testNasopharyngeal swab sampling for COVID-19

    The healthcare provider will gently insert the swab a short distance (1-1.5 cm for young children) into one nostril, reaching the back of the nasal cavity. The swab will then be gently rotated and rubbed for a few seconds to collect a sample of mucus. The same process may be repeated in the other nostril.

06

What researchers measure

Primary outcomes

  1. Severe acute COVID-19 infection (SACI)

    The percentage of patients diagnosed with SACI among all patients admitted to the Emergency Department

    Time frame: Up to 16 weeks

Secondary outcomes

  1. Administration of low-flow oxygen therapy via nasal cannula or face mask

    The percentage of COVID-19 patients treated with low-flow oxygen among all patients admitted to the Emergency Department

    Time frame: Up to 12 weeks

  2. Administration of high-flow oxygen via nasal cannula (HFNC), or administration of oxygen via bilevel or continuous positive airway pressure (CPAP) machine

    The percentage of COVID-19 patients treated with HFNC or CPAP among all patients admitted to the Emergency Department

    Time frame: Up to 12 weeks

  3. Treatment with mechanical ventilation

    The percentage of COVID-19 patients treated with mechanical ventilation among all patients admitted to the Emergency Department

    Time frame: Up to 12 weeks

  4. Treatment with extracorporeal membrane oxygenation (ECMO)

    The percentage of COVID-19 patients treated with ECMO among all patients admitted to the Emergency Department

    Time frame: Up to 8 weeks

  5. Treatment with vasopressor support

    The percentage of COVID-19 patients treated with vasopressor support among all patients admitted to the Emergency Department

    Time frame: Up to 8 weeks

  6. Length of ICU stay

    Mean duration of ICU stay for patients admitted with COVID-19

    Time frame: Up to 16 weeks

  7. Length of hospital stay

    Mean duration of hospital stay for patients admitted with COVID-19

    Time frame: Up to 24 weeks

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Aug 2026, 23 months after the start.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 23 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
May 30, 2024
StartActual
Sep 30, 2024
Primary completionEst.
Aug 31, 2026
CompletionEst.
Aug 31, 2026
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06434701
Collaborators
London North West Healthcare NHS Trust
Responsible party
Itai Shavit (Chair, Division of Pediatrics, Hadassah Medical Center, Hadassah Medical Organization) — Principal investigator
First posted
May 30, 2024
Start date
Sep 30, 2024
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Mar 14, 2025

Study contacts

Itai Shavit, MD
Contact
shavit1@hadassah.org.il
00 972 50 2063239
Hadas Lamberg, PhD
Contact
lhadas@hadassah.org.il
00 972 2 6777572

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion